Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block

Phase 1

Not yet recruiting

• Conditions: Trauma Injury
• Interventions: Drug: Dexmedetomidine injection

• Registration Number: NCT06304909
• Lead Sponsor: Assiut University

Brief Summary

Effect of intravenous dexmedetomidine versus dexamethasone for management of repound pain after supraclavicular brachial plexus block.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-05
• Study First Submitted QC: 2024-03-08
• Study First Posted: 2024-03-12
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-20
• Last Update Posted: 2024-04-23
• Study Start: 2024-05
• Primary Completion: 2025-03
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 111

Inclusion Criteria

• Patients between 20_60 years old

  • Patients with ASA clinical status I/II
  • Patients scheduled for peripheral nerve block for upper extremity surgery

Exclusion Criteria

• 1. they refused to participate 2) had preexisting neuropathy of the surgical limb 3) hypersensitivity to amide anesthetic 4) significant pulmonary disease 5) coagulopathy 6) sepsis 7) infection at the block site 8) hypersensitivity to dexmedetomidine & dexamethasone

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Dexmedetomidine group will receive 0.5 mcg/kg	Dexmedetomidine injection	-
Dexamethasone group will receive 8mg/kg	Dexmedetomidine injection	-
Control group will receive equivalent volume of saline 0.9%.	Dexmedetomidine injection	-

Primary Outcome Measures

Name	Time	Method
The incidence of rebound pain.	1year	Rebound pain is defined as an increase from well-controlled to severe pain typically within 12_24 h of resolution of the nerve block.